CN1478511A - Application of crude medicinal material in the preparation of medicine for treating dyssomnia - Google Patents
Application of crude medicinal material in the preparation of medicine for treating dyssomnia Download PDFInfo
- Publication number
- CN1478511A CN1478511A CNA031214290A CN03121429A CN1478511A CN 1478511 A CN1478511 A CN 1478511A CN A031214290 A CNA031214290 A CN A031214290A CN 03121429 A CN03121429 A CN 03121429A CN 1478511 A CN1478511 A CN 1478511A
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- medicine
- ziziphi spinosae
- sleep disorder
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of wild jujube leaf in preparing the medicine for treating somnipathy is disclosed. A process for extracting the active component of wild jujube leaf includes decocting, concentrating and drying. Its advantages are high curative effect and no toxic by-effect.
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of sleep disorder, particularly relating to a kind of is the medicine of crude drug preparation treatment sleep disorder with the Folium Ziziphi Spinosae.
Background technology
The medicine of treatment sleep disorder has Western medicine and Chinese medicine at present, and the defective of Western medicine is that side effect is arranged, and is easy to generate dependency; Chinese medicine mostly is compound formulation, and composition is complicated, and treatment is based on conditioning, and curative effect is slow and not obvious.
Summary of the invention
The purpose of this invention is to provide the application of Folium Ziziphi Spinosae crude drug in the medicine of preparation treatment sleep disorder, and the medicine that utilizes the treatment sleep disorder of Folium Ziziphi Spinosae crude drug preparation, this medicine is nontoxic to human body, have no side effect, and the various patients that suffer from sleep disorder are had very significantly curative effect.
The application of a kind of crude drug of the present invention in the medicine of preparation treatment sleep disorder, described crude drug is a Folium Ziziphi Spinosae.
A kind of medicine for the treatment of sleep disorder of the present invention, its active ingredient is an extract in the Folium Ziziphi Spinosae, concrete extraction step is: decocting, and----drying obtains active ingredient to concentrate----.
A kind of medicine for the treatment of sleep disorder of the present invention, its active ingredient is an extract in the Folium Ziziphi Spinosae, its extraction step is:
A. prepare Folium Ziziphi Spinosae;
B. decocting;
C. concentrate;
D. with methanol or ethanol lixiviate;
E. alcohol is removed in immersion, concentrates;
F. n-butanol extraction;
G. alkali proposes the active ingredient in the butanol extraction liquid;
H. get active ingredient after the acid neutralization.
The present invention is potassium hydroxide or sodium hydroxide at the alkali described in the said extracted step f.
The present invention is a kind of to be treated in the medicine of sleep disorder, the ingredient requirement of described Folium Ziziphi Spinosae, meet GB/T5009.57-1996 Folium Camelliae sinensis sanitary standard, the appearance index of Folium Ziziphi Spinosae: single leaf alternate, the blade ellipse is to ovum shape lanceolar, long 2-3.5cm, wide 6-12mm, there is serration at the edge, 3 of master pulses, color and luster is green, abnormal smells from the patient delicate fragrance, sweet.The appearance test visual method of Folium Ziziphi Spinosae, sense index are that checking matter is placed on the blank sheet of paper of cleaning, under natural light, and visual inspection, color and luster, tissue morphology, sweet, the delicate fragrance of abnormal smells from the patient.
A kind of preparation for the treatment of the medicine of sleep disorder of the present invention, described dosage form is tablet, capsule, also friendship is as the additive of health food.
The present invention treats the medicine of sleep disorder, and the active ingredient of extracting from Folium Ziziphi Spinosae has following effect through animal experimental observation: one, to central nervous system's inhibitory action: 1, the influence of laboratory animal outward appearance behavioral activity:
3 groups of mices (10 every group), Sc normal saline respectively, the 0.056g/ active ingredient is the outward appearance behavioral activity of each group mice before the administration and after the administration relatively, as a result, after mice was given normal saline, no significant change was moved in behavior, animal activity obviously reduces after giving active ingredient, it is motionless to lie prostrate, and closes order, drowsiness, stimulate to external world and still respond, but than dozing late before the administration, other mends 10 tests of rat, and the result is similar to the mice situation.2, to the influence of mice autonomic activities:
2 groups of mices (2 every group), Po normal saline and 0.028g/Kg active ingredient were put into photoelectricity activity inventory instrument with two groups after 20 minutes respectively, and after conforming earlier 5 minutes, opening entry is respectively organized the movable number of mice in 10 minutes.Experiment repeats 7 times, the result, and the Ns group is 222.9 ± 17.1 times, the active ingredient group is 141.1 ± 21.5 (P＜0.01=.Other gets 2 groups of mices (3 every group) respectively Sc normal saline and 0.028g/Kg active ingredient, and after 20 minutes, the movable number in the mice 10 minutes is respectively organized in immediate record, and experiment repeats 6 times, and the result is 459.5 ± 60.3 times and 335.0 ± 52.8 (P＜0.01=.Two, with the synergism of thiopentone:
2 groups of (20 every group) difference SC normal saline of mice and 0.056g/Kg active ingredient are after 30 minutes, and each organizes mice IP40mg/kg thiopentone, and record each group sleep number of mice and sleep time the results are shown in Table I.
Table I
Three, with the antagonism of amfetamine:
| Mus number (only) | Sleep Mus number | The P value | Sleep time | The P value | |
| The NS+40mg thiopentone | ????20 | ??8 | ??3.2± ??2.1 | ||
| 0.056g/Kg active ingredient+40mg thiopentone | ????20 | ??20 | ＜0.001 | ??20.3±2.6 | ＜0.001 |
3 groups of mices (3 every group), first group SC and ip normal saline, second group Sc normal saline and ip3mg/Kg amfetamine, third group of Sc0.028g/Kg active ingredient and 3mg/Kg amfetamine, after 30 minutes, measure the movable number of respectively organizing mice with photoelectric method, experiment repeats 6 times, the result is 336.2 ± 38.6 times, 606.2 ± 63.6 (P＜0.001=and 335.5 ± 45.9 (P＜0.001=.Four, analgesic activity:
20 of mices, survey normal pain valve with hot plate method after, each surveys bitterly valve once after 30 minutes and 60 minutes in po0.336g/Kg active ingredient administration, the result is respectively 15.3 ± 0.8,30.2 ± 1.8 (P＜0.001=and 26.05 ± 1.3 seconds (P＜0.001=.Five, to the influence of normal rat temperature:
15 of rats, measure the rectal temperature secondary with thermister earlier, (15 minutes at interval), get the normal value of average before as administration, Sc0.056g/Kg active ingredient then, respectively surveyed body temperature once in 1 and 1.5 hour after the administration, the result is 38.7 ± 0.2 times, 37.0 ± 0.2 (P＜0.001=and 36.8 ± 0.2 ℃ (P＜0.001).
This laboratory observation is inhibited to laboratory animal outward appearance behavioral activity and autonomic activities to active ingredient, can strengthen the inhibitory action of thiopentone to the central nervous system, the excitation of antagonism amfetamine, and the effect of analgesia and reduction normal rat body temperature is still arranged, and experimental result illustrates that tentatively active ingredient has inhibitory action to the central nervous system.
The Folium Ziziphi Spinosae active ingredient is at the laboratory observation on the sedation: the influence of, measuring the thiopentone effect under mice autonomic activities and the valve:
4 groups of mices (2 every group), SC normal saline respectively, 100,200 and the 400mg/Kg active ingredient, measured the movable number of group in 30 minutes later on the light method, experiment repeats 10 times, respectively organizes mice IP30mg/Kg thiopentone after preceding 5 experiments, each group sleep number of mice of record the results are shown in Table II.
Table II
Two, the effect of metering chloral hydrate is influential down for mice passive activity and valve:
| Experimental group number (Mus number) | The movable number of mice (X ± SD) | The P value | Sleep Mus number/experimental mouse sum | The P value | |
| The NS group | ?10(20) | 825.9± | ??0/10 | ||
| 100mg/Kg | ?10(20) | 829.7± | ??2/10 | ||
| 200mg/Kg | ?10(20) | 625.5± | ＞0.05 | ??3/10 | ??＞0.05 |
| 400mg/Kg | ?10(20) | 497.7± | ＜0.001 | ??7/10 | ??＜0.01 |
4 groups of mices (2 every group), ip normal saline respectively, 100,200 and the 400mg/Kg active ingredient, after 30 minutes, measure 10 minutes with rotating rods method in each group number of mice of falling, survey and finish, each organizes mice all in offside ip180mg/Kg chloral hydrate, each group sleep number of mice of record.Experiment is carried out 5 times again, the results are shown in Table III.
Table III
Three, valve measures the synergism of pentobarbital sodium down:
| Experimental mouse number (only) | Mus number (only) falls | Sleep Mus number (only) | The P value | |
| The NS group | ??10 | ??0 | ??0 | |
| ?100mg/Kg | ??10 | ??1 | ??1 | |
| ?200mg//Kg | ??10 | ??1 | ??5 | ??＜0.01 |
| ?400mg//Kg | ??10 | ??0 | ??7 | ??＜0.01 |
4 groups of mices (11 every group), ip normal saline respectively, 100,200 and the 400mg/Kg active ingredient, after 30 minutes, each organizes mice all in offside ip22mg/kg pentobarbital sodium, the Mus number of each group sleep of record, the result is respectively 0/11,2/11,5/11 (P＜0.05=9/11 (P＜0.001).Four, with the antagonism of amfetamine:
4 groups of mices (2 every group), one group of Sc and ip normal saline, another group Sc normal saline and ip5mg/Kg amfetamine, surplus two groups of amfetamine that are respectively Sc200 and 400mg/Kg active ingredient and the above-mentioned dosage of ip, after 30 minutes, measure the movable number of respectively organizing in the mice 10 minutes by last photoelectric method, experiment repeats 5 times, the result is respectively 677.0 ± 58.3,2267.0 ± 61.4,1967.2 ± 53.3 (P＜0.01=and 1798.6 ± 32.5 (P＜0.001).Five, to the influence of solitary mice Ou Dou aggressive behavior:
The solitary male mice that choosing has the Ou Dou aggressive behavior divides 3 groups at random, every group 10, difference ip normal saline, 200 with the 400mg/Kg active ingredient, after observing administration, when 30 minutes and 60 minutes, each group suppresses number of mice result, effective ingredient to solitary male mice Ou Dou aggressive behavior do not have obvious influence.
This laboratory observation has obvious inhibitory action to effective ingredient to the mice autonomic activities, the barbital sodium of dosage, thiopentone and aldehydrol merge application under this effective ingredient and the valve, are synergism, merge with amfetamine and use, be antagonism, show that active ingredient has the maincenter sedation.
It is lonely from the Ou Dou of mice aggressive behavior that known tranquilizer can suppress, and this product does not have this effect, and the two interaction property difference is described.
The invention has the beneficial effects as follows: the medicine of active ingredient treatment sleep disorder in adopting Folium Ziziphi Spinosae, it not only has curative effect preferably to the various patients that suffer from sleep disorder, and nontoxic, have no side effect, do not have dependency, can life-time service.
The specific embodiment
Embodiment one
The medicine of present embodiment treatment sleep disorder, its active ingredient is an extract in the Folium Ziziphi Spinosae, its step is decocting, and----drying obtains active ingredient to concentrate----.
Concrete extraction step:
A. prepare Folium Ziziphi Spinosae 1000g, meet GB/T5009.57-1996 Folium Camelliae sinensis health
Standard;
B. decocting adds the water of 10 times of volumes;
C. concentrate, it is concentrated into 2 times of water;
D. dry, get coarse dry powder 100g.
Extract with the 1000g Folium Ziziphi Spinosae and to obtain active ingredient coarse dry powder 100g, 333 of the medicine grains that to can be made into every medicine active ingredient coarse dry powder content be the 300mg/ grain are once taken medicine 2 before sleeping every day, can take 167 days for a people.
Embodiment two
The medicine of present embodiment treatment sleep disorder, its active ingredient is an extract in the Folium Ziziphi Spinosae, its extraction step is:
A. prepare Folium Ziziphi Spinosae 1000g, meet GB/T5009.57-1996 Folium Camelliae sinensis health
Standard;
B. decocting adds the water of 10 times of volumes;
C. concentrate, it is concentrated into 2 times of water;
D. use the ethanol lixiviate,, merge three times and soak with 8 times of amounts, 70% ethanol lixiviate three times
Liquid;
E. alcohol is removed in immersion, is concentrated into 2/3 of leaf amount;
F. n-butanol extraction;
G proposes active ingredient in the butanol extraction liquid with potassium hydroxide or sodium hydroxide;
H. get active ingredient after the acid neutralization.
Extract with the 1000g Folium Ziziphi Spinosae and to obtain active ingredient 6.0g, 300 of the medicine grains that to can be made into every medicine effective component content be 20mg are once taken medicine 2 before sleeping every day, can take 150 days for a people.
Claims (4)
1. the application of crude drug in the medicine of preparation treatment sleep disorder, it is characterized in that: described crude drug is a Folium Ziziphi Spinosae.
2. a medicine for the treatment of sleep disorder is characterized in that, its active ingredient is an extract in the Folium Ziziphi Spinosae, and concrete extraction step is: decocting, and----drying obtains active ingredient to concentrate----.
3. the medicine of treatment sleep disorder as claimed in claim 2 is characterized in that, its active ingredient is an extract in the Folium Ziziphi Spinosae, and its extraction step is:
A. prepare Folium Ziziphi Spinosae;
B. decocting;
C. concentrate;
D. with methanol or ethanol lixiviate;
E. alcohol is removed in immersion, concentrates;
F. n-butanol extraction;
G. alkali proposes the active ingredient in the butanol extraction liquid;
H. get active ingredient after the acid neutralization.
4. the medicine of treatment sleep disorder as claimed in claim 3 is characterized in that, its active ingredient is an extract in the Folium Ziziphi Spinosae, is potassium hydroxide or sodium hydroxide at the alkali described in the extraction step f.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031214290A CN1478511A (en) | 2003-03-28 | 2003-03-28 | Application of crude medicinal material in the preparation of medicine for treating dyssomnia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031214290A CN1478511A (en) | 2003-03-28 | 2003-03-28 | Application of crude medicinal material in the preparation of medicine for treating dyssomnia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1478511A true CN1478511A (en) | 2004-03-03 |
Family
ID=34152810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031214290A Pending CN1478511A (en) | 2003-03-28 | 2003-03-28 | Application of crude medicinal material in the preparation of medicine for treating dyssomnia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1478511A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773564B (en) * | 2010-01-21 | 2012-05-30 | 西北农林科技大学 | Method for extracting alkaloid from Semen hoveniae and method for purifying Semen hoveniae alkaloid |
| CN105687367A (en) * | 2016-01-25 | 2016-06-22 | 西北大学 | Red jujube leaf standard extract, as well as preparation method and application thereof |
-
2003
- 2003-03-28 CN CNA031214290A patent/CN1478511A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101773564B (en) * | 2010-01-21 | 2012-05-30 | 西北农林科技大学 | Method for extracting alkaloid from Semen hoveniae and method for purifying Semen hoveniae alkaloid |
| CN105687367A (en) * | 2016-01-25 | 2016-06-22 | 西北大学 | Red jujube leaf standard extract, as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382822C (en) | Herb medicine | |
| KR20070054222A (en) | Medicine having analgesic effects | |
| CN104013878B (en) | A kind of lavipeditum medicine vinegar and preparation method thereof for treating tinea pedis | |
| CN103623046A (en) | Composite playing auxiliary protection role in chemical and alcoholic liver injury, preparation method of composite and application of composite in health-care food | |
| US20210100860A1 (en) | Use of compositions of water/alcohol extracts of antrodia cinnamomea cut-log wood cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| RU2535019C1 (en) | Sedative and spasmolytic agent | |
| CN1478511A (en) | Application of crude medicinal material in the preparation of medicine for treating dyssomnia | |
| CN107551001A (en) | A kind of Chinese herbal compounds and its preparation method for being used to prevent and treat alcoholic liver injury | |
| CN102612370B (en) | dietary supplement stimulating the male sexual function | |
| CN107095870B (en) | A kind of compound medicament composition and application thereof with anti-lymphadenoma effect | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN102716206B (en) | Application of meridian warming and activating formula to preparation of medicine for preventing oxaliplatin (OXA)-induced peripheral neuropathy side effect | |
| CN1899586A (en) | Chinese medicine preparation for treating gynecologic inflammation and its preparing method | |
| CN1299758C (en) | Anti-depression traditional medicinal composition and its preparation method | |
| CN117731749B (en) | Medicine and food homologous traditional Chinese medicine composition for treating cancer pain and preparation method and application thereof | |
| CN103977076B (en) | Fructus schizandrae total lignans are being prepared for treating the application in the medicine coughed | |
| CN1788764A (en) | Traditional Chinese medicine formulation for improving pulmonary fibrosis | |
| CN100340271C (en) | Hypoglycemic medicine for treating diabetes and its prepn process | |
| CN1911329A (en) | Traditional Chinese medicine composition for preventing and/or adjuvant therapy of malignant tumor | |
| CN109498701A (en) | A kind of Chinese medicine composition and its preparation method and application for preventing and treating goose paramyxovirus | |
| Kolekar et al. | Formulation and Evaluation of Paediatric Herbal Chocolate | |
| CN1310650C (en) | Application of saponins in the preparing process of coxsackie virus resisting medicine | |
| CN103977019B (en) | Fruit of Chinese magnoliavine total starches is used for treating the application in the medicine of cough or health products in preparation | |
| Haghparast et al. | Involvement of dopaminergic system in the dentate gyrus of the hippocampus in modulating the orofacial pain-related behaviors in the rats | |
| CN1161142C (en) | Medicinal composition for improving memory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |